A Phase 2 interventional study of SGLT-2 inhibitors and Placebo in Atrial Fibrillation (AF) and Hypertension, sponsored by Huashan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Huashan Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing SGLT2 inhibitors in Atrial Fibrillation — 9 open to participants now, 10 under way, 5 of them phase 3. A drug class: SGLT2 inhibitors · Atrial Fibrillation.
Among the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation, this one is the 13th largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 2, and was the 13th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →9 of the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation are open now, in 7 countries. Recruiting first, the newest first:
Region Stockholm · Sites in Sweden
Ages 55+
Yonsei University · Sites in Korea, Republic of
Ages 19–84
University of East Anglia · Sites in United Kingdom
Ages 18+
Region Örebro County · Sites in Czechia, Denmark, Sweden
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 6 · Phase 4 5
First in 2021; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 66 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 280 across the 15 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
Huashan Hospital is the lead sponsor of 248 studies on the registry; 105 are open to participants now.
Huashan Hospital has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
5 of the studies testing SGLT2 inhibitors in Atrial Fibrillation that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111443Phase 3Chang Gung Memorial HospitalEffect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation | 2026-11-30 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT07482020Huashan HospitalSGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism | 2026-12-30 |
| NCT06528262Yonsei UniversityEffect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation | 2027-05-31 |
| NCT07776054Samsung Medical CenterClinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Heart failure is the most important clinical endpoint event in atrial fibrillation (AF). Patients with AF complicated by heart failure have a significantly higher risk of all-cause mortality and cardiovascular mortality compared to those without heart failure. Abnormal left atrial function is an important mechanism leading to the occurrence of AF-related heart failure. Therefore, it is essential to find drugs that can improve left atrial function to prevent heart failure in patients with AF. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are important drugs for regulating metabolic abnormalities. Studies have found that these drugs also reduce the risk of new-onset AF in patients with heart failure. Thus, the investigators hypothesize that SGLT2i may be able to regulate left atrial function.
This study is a multicenter randomized controlled trial using three-dimensional speckle tracking echocardiography to investigate whether SGLT2i can improve left atrial function and prevent heart failure in patients with paroxysmal AF who have hypertension and metabolic disorders, compared to placebo. The investigators also observed the effects of SGLT2i on cardiovascular and metabolic risk factors. The investigator team has a solid foundation in the field of cardiovascular metabolism, having completed the evaluation of left atrial function in paroxysmal AF using three-dimensional speckle tracking technology over the past three years. This study is the first to propose that SGLT2i can improve left atrial function in paroxysmal AF patients with metabolic abnormalities, which is of great significance for preventing heart failure in this type of AF.
Research Endpoints:
Follow-up Medication Use:
Inclusion Criteria:
Exclusion Criteria:
Withdrawal Criteria:
Research Process: Applicable to all centers
Measurement Methods and Techniques for the Main Observation Indicators in This Study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients aged 18-80 years, treated in the outpatient or inpatient departments of each research center and included in the AF database.
Exclusion Criteria:
Atrial fibrillation caused by severe mitral stenosis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SGLT-2 inhibitors
Drug: Placebo
empagliflozin (10mg qd)
PLACEBO
LA strain (LASI)
Using three-dimensional speckle tracking technology to measure longitudinal strain during the reservoir phase (LASr).Using TDI to measure E/e'. The LASI is calculated by these two parameter and can indicate left atrial strain.
Time frame: from enrollment to the end of treatment at 12 months
circumferential strain (LASr-c)
Using three-dimensional speckle tracking technology to measure
Time frame: From enrollment to the end of treatment at 12 months
conduit phase (LAScd)
Using three-dimensional speckle tracking technology to measure
Time frame: From enrollment to the end of treatment at 12 months
hospitalization due to heart failure
Record events of subjects visiting or being hospitalized due to heart failure during the follow-up period. This endpoint includes patients who present with symptoms such as dyspnea, fatigue, and orthopnea during the follow-up period, and have an NT-proBNP level greater than 300pg/ml detected in the emergency department, outpatient clinic, or inpatient department, with a documented diagnosis.
Time frame: From enrollment to the end of treatment at 12 months
changes in blood pressure
Patients undergo standardized office blood pressure monitoring (OBPM) using automated oscillometric devices or manual sphygmomanometry with appropriate cuff sizes. Measurements are obtained after 5 minutes of seated rest, with feet flat on the floor and arm supported at heart level. Two to three readings are taken 1-2 minutes apart, and the average is recorded. Take the blood pressure test for every month. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period.
Time frame: From enrollment to the end of treatment at 12 months
change in blood glucose
Patients undergo venous blood sampling after 8-12 hours of overnight fasting. Measurements are performed using standardized enzymatic methods (hexokinase or glucose oxidase). HbA1c is measured via high-performance liquid chromatography (HPLC) or immunoassay. FPG monthly; HbA1c every 3 months. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period.
Time frame: From enrollment to the end of treatment at 12 months
Change in lipid metabolism
Fasting venous blood sampling (12-14 hours overnight fast) followed by Enzymatic colorimetric assays for TC, TG, and HDL-C. Testing is done every month. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period.
Time frame: from enrollment to the end of treatment at 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SGLT2 inhibitors